| Somanetics Corporation has signed an Exclusive Sublicense Agreement with Raba Equity Partners II, LLC. Under terms of the agreement, Somanetics has obtained exclusive rights, subject to specified rights of the U.S. Government and rights retained by The Johns Hopkins University, to new cerebral autoregulation technology developed at The Johns Hopkins University. Integration of this technology into Somanetics' INVOS Cerebral/Somatic Oximeter would yield the first noninvasive monitor providing cerebral autoregulation data for routine clinical use. The cerebral autoregulation technology is associated with two pending patents. Somanetics has provided Raba coreFoundry an up-front, non-refundable payment of $1.8M and will pay a royalty on future revenue associated with the technology. The up-front payment will be accounted for as a research and development expense in Q409. :theflyonthewall.com |
